Published November 30, 2024 | Version v1
Journal article Open

Polycystic ovary syndrome: risk factor for reproductive age women's: epidemiological study in Iraq

Authors/Creators

  • 1. 1Assiss- Prof- Ph.D .Community Health Nursing Department, College of Nursing, University of Al-Ameed, Ministry of Higher Education and Scientific Research, Iraq.

Description

Background: One of the most widespread endocrine issues affecting women of reproductive age is PCOS, which is also one of the main reasons of infertility. Cysts are not harmful, but they do cause hormonal problems, that can cause period problems and make it difficult to conceive1.

Study Material: A quantitative study design (case-control study) was Carrie out in order to achieve the stated objective that include to identify of the polycystic ovary syndrome risk factors in women of reproductive age. The study is  begun from July 7, 2021 to September 16, 2021 in Karbala Governmental. Sample and sampling: Study Sample non-probability Purposive sample of 61 control case and 50 study case woman’s.

Results: The study results that   the indicate different between control and study groups) for risk factors among (PCOS) for study sample. This table explain according to difference according to (Odd ratio) which there is that the no different between control and group study among patient risk   factors (variable (PCOS such as (bad mood, Family History of diabetes, Fast food, Physical activity, discharge, and body mass index (0.84, o.80, 0.59, 0.79, 0.66, 0) respectively. While there is effect of risk factors among study groups for variables are (PCOS in the family, infertility in the family, regular menstruation in the mother, and dietary) (2.71, 2.97, 1.55, and 1.22) respectively.

Conclusion: The study conclude the most the study sample   for control study is (26-31) years and (19) years for study groups within and within level of education have academic study for control and secondary school for study. The study conclude by determine risk factors for poly cyst syndrome through comparison between case and study groups are PCOS in the family, infertility in the family, regular menstruation in the mother, and dietary.

Files

5 Polycystic ovary syndrome.pdf

Files (266.7 kB)

Name Size Download all
md5:fec25cc7f7a46efef702bb3f0b7847fa
266.7 kB Preview Download

Additional details

References

  • 1. Suhas D, Suresh D, Panchshila D. Review on Introduction to PCOS and their management. J Sci 2015;5:208-12.
  • 2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–2749.
  • 3. Mahmood M, El-Basel M, Sheta M. Polycystic ovary syndrome in premenopausal women with type 2 diabetes mellitus: prevalence, characters and related morbidity. Med J Cairo Univ. 2009;77(4):327–335.
  • 4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12): 1223–1236.
  • 5. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition. 2002;18(10):872–879.
  • 6. Tošić-Pajić J, Šeklić D, Radenković J, et al. Augmented oxidative stress in infertile women with persistent chlamydial infection. Reprod Biol. 2017;17(2):120–125.
  • 7. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:28.
  • 8. Poston L, Igosheva N, Mistry HD, et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr. 2011;94(Suppl_6):1980S– 1985S.
  • 9. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N. Increased prolidase activity and oxidative stress in PCOS. Clin Endocrinol (Oxf). 2013;79(1):105–110.
  • 10. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016:8589318.
  • 11. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013;19(3):268–288.
  • 12. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-60.
  • 13. Rajashekar L, Krishna D, Patil M. Polycystic ovaries and infertility: our experience. J Hum Reprod Sci 2008;1:65-72.
  • 14. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;2:CD007506.
  • 15. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-83.
  • 16. Melo AS, Vieira CS, Barbieri MA, et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum Reprod. 2010;25:2124–2131.
  • 17. Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: the role of vitamin D. Rev Endocr Metab Disord. 2017;18: 273–283.
  • 18. Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: the role of vitamin D. Rev Endocr Metab Disord. 2017;18: 273–283.
  • 19. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Am J Obstet Gynecol. 2011;204:558.e1– 558.e6.
  • 20. Boomsma CM, Eijkemans MJC, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673–683.
  • 21. Mani H, Davies MJ, Bodicoat DH, et al. Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clin Endocrinol (Oxf). 2015;83(4):542–549.
  • 22. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57(3):343–350.
  • 23. SD. Reed, D. Scholes, AZ. LaCroix, LE. Ichikawa, WE. Barlow, SM. Ott, et al., "Longitudinal changes in bone density in relation to oral contraceptive use," Contraception, 68, pp. 177-82, 2003.
  • 24. M. Gambacciani, B. Cappagli, M. Ciaponi, C. Benussi, AR. Genazzani, "Hormone replacement therapy in perimenopause: Effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics," Menopause, 6, pp. 43-8, 1999.
  • 25. M. Gambacciani, B. Cappagli, V. Lazzarini, M. Ciaponi, F. Fruzzetti, AR. Genazzani, et al., "Longitudinal evaluation of perimenopausal bone loss: Effects of different low dose oral contraceptive preparations on bone mineral density," Maturitas 54, pp. 176-80, 2006.
  • 26. Hashimoto K, Nozaki M, Inoue Y, Sano M, Nakano H. The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: the correlation with specific markers of bone metabolism. Maturitas 1995;22:185–91.
  • 27. Kalkwarf HJ, Specker BL. Bone mineral changes during pregnancy and lactation. Endocrine 2002;17:49–53.
  • 28. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000; 15:1965–73.
  • 29. S. Benson, P. Arck, S. Tanc, S. Hahn, K. Mann, N. Rifaie, et al., "Disturbed stress responses in women with polycystic ovary syndrome," Psychoneuroendocrinology, 34, pp. 727—735, 2009.
  • 30. H. Escobar-Morreale, J. Botella-Carretero, F. lvarez-Blasco, J. Sancho, J. San Milla´n, "The Polycystic Ovary Syndrome Associated with Morbid Obesity May Resolve after Weight Loss Induced by Bariatric Surgery," J Clin Endocrinol Metab, 90 (12), pp. 6364– 6369, 2005.Begum S, Shariff A, Ayman G, Mohammad B, Housam R, Khaled N. Prevalence of polycystic ovarian syndrome among students of RAK Medical and Health Sciences University, United Arab Emirates. International Journal of Medicine and Pharmaceutical Science. 2016;6:109–118.
  • 31. B. Keevil, "Steroid Mass Spectrometry for the Diagnosis of PCOS," Med. Sci. 7, pp. 78, 2019.
  • 32. J. Mellembakken, S. Berga, M. Kilen, T. Tanbo, T. Abyholm, P. Fedorcsak, "Sustained fertility from 22 to 41 years of age in women with polycystic ovarian syndrome," Human Reproduction, 26(9), pp. 2499–2504, 2011.
  • 33. R. Azziz, K. Woods, R. Reyna, T. Key, E. Knochenhauer, B. Yildiz, "The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population," J Clin Endocrinol Metab, 89(6), pp. 2745–2749, 2004.
  • 34. T. Du, Y. Duan, K. Li, X. Zhao, R. Ni, Y. Li, D. Yang, "Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome," BioMed Research International, 10 (1), pp. 7, 2015.
  • 35. S.Qureshi, K. Shah, J. Gupta, N. Upmanyu, "Prevalence and risk factor of polycystic ovarian syndrome," Asian J Pharm Clin Res, 9(2), pp. 23-25, 2016.
  • 36. Karakas SE, Kim K, Duleba AJ. Determinants of impaired fasting glucose versus glucose intolerance of polycystic ovary syndrome. Diabetes Care 2010; 33(4): 887-893.
  • 37. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess- PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr 2013; 162(5): 937-941.
  • 38. Tian XX, Ruan XY, Wang J, Liu SY, Yin DM, Lu YJ, et al. Analysis of risk factors for 437 cases of polycystic ovary syndrome. J Cap Univ Med Sci 2014; 35(4): 414-418.
  • 39. Bates GW, Legro RS. Longterm management of polycystic ovarian syndrome (PCOS). Mol Cell Endocrinol 2013; 373(1–2): 91-97.
  • 40. Xiao WH, Qiu XY, Zhang T, Zhuang AW. Study on the mood of polycystic ovarian syndrome patients. Zhejiang J Trad Chin Med 2011; 46(11): 795-796.
  • 41. Le Donne M, Alibrandi A, Giarrusso R, Lo Monaco I, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva Ginecol 2012; 64(1): 23-29.